Pressure BioSciences, Inc. : Pressure BioSciences Reports Significant Progress in the Development of a PCT-based Method to Improve Processing of Sexual Assault Samples

"Company") today announced measurable progress in the development of a new procedure for the
selective extraction of male DNA from mixtures of male and female cells. The project's goal is to
improve the processing of sexual assault evidence kits (also called "rape kits"); the new procedure is
based on the Company's patented Pressure Cycling Technology ("PCT"). The data were reported at the
recent 17th Latin-American Symposium on Biotechnology, Biomedical, Biopharmaceutical, and Industrial
Applications of Capillary Electrophoresis and Microchip Technology ("LACE 2011"). This international
conference was held from December 2-6, 2011 in Hollywood, Florida.

Dr. Bruce R. McCord, Associate Director of the International Forensic Research Institute (IFRI),
Department of Chemistry and Biochemistry, Florida International University (FIU), and Ms. Deepthi
Nori, MFS from the IFRI - FIU, presented the study, which was entitled Application of Pressure Cycling
Technology (PCT) in Differential Extraction. Dr. McCord and Ms. Nori are working on the development
of a unique, PCT-based method to differentially extract DNA from sperm and vaginal epithelial cells in
the same mixture. Dr. McCord and Ms. Nori believe that this novel method has the potential to
significantly decrease rape kit processing time, increase throughput, decrease costs, and improve results.
They also believe that it may lead to better identification of criminals involved in sexual assaults, by
helping to confirm suspect and victim contact.

the selective extraction of male DNA from sperm cells in the presence of much larger quantities of female
DNA. This is accomplished by first separating the sperm and non-sperm fractions. This processing step
is essential, yet it remains difficult, complex, time-consuming, and not aligned with automation. It is
truly a serious bottleneck in sexual assault casework."

kits nationwide, and an estimated 180,000 new sexual assault cases each year, it is essential that improved
methods for processing rape kits be developed. We believe that the data reported by Dr. McCord and Ms.
Nori indicate that PCT can potentially increase the recovery of DNA from sperm cells, without the need
for a long and laborious separation step. Based on their findings, we believe their unique PCT-based
method could result in better quality of results and significantly increased throughput, which in turn could
result in a reduction in the rape kit backlog and an increase in arrest rates for sex crimes. And for PBI
shareholders, we believe this method could result in significant increases in Barocycler instrument
placements and product revenue in 2012 and beyond."

Dr. Bruce McCord said: "Our goal is to develop a PCT-based method that can selectively disrupt sperm
cells in mixtures containing female cells, without the need to first separate the cells. At the LACE 2011
Meeting, we reported on the successful completion of this important processing step in laboratory
samples. We have now begun to test this unique approach in complex mixtures and real sexual assault
evidence kit samples. We expect to report on these new studies at the annual American Academy of
Forensics Sciences ("AAFS") Conference in February, and at other venues throughout the year."

About Pressure BioSciences
Pressure BioSciences, Inc. ("PBI") (NASDAQ: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated $6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for mass spectrometry, biomarker discovery, bio-therapeutics characterization, vaccine development, soil and plant biology, forensics, histology, and counter-bioterror applications.

Forward-Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs,
expectations, or predictions of the future are "forward-looking" statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements
regarding the expected advantages of PBI's PCT product line in processing rape kit samples; the potential
for PCT as a tool for the differential extraction of DNA from sperm cells and epithelial cells, without the
need for prior separation; that the PCT method has the potential to significantly decrease rape kit
processing time, increase throughput, decrease costs, improve results, lead to better identification of
criminals involved in sexual assaults, confirm suspect and victim contact, and help prove innocence; that
the PCT method could result in an increase in product sales in 2012 and beyond; and the number of
unprocessed rape kits and the number of new sexual assault cases each year. These statements are based
upon PBI's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and
other factors that could cause actual outcomes and results to differ materially from those indicated by
these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited
to: unforeseen technological difficulties or business issues in the implementation of the PCT method in
the processing of rape kits that may impede or prevent the achievement of the expected advantages of the
PCT method for such processing; due to unforeseen technical difficulties, or marketing, sales, and
distribution difficulties, the PCT method may not be adopted by the forensics community as an accepted
workflow for rape kit sample preparation or the forensics community may not perceive the benefits of
PCT for sample preparation; if actual operating costs are higher than anticipated, or revenues from
product sales are less than anticipated, the Company may need additional capital prior to March 2012; and
if the Company fails to achieve its plan to regain compliance with the NASDAQ Listing Rules for
minimum stockholders' equity and the minimum bid price of $1.00 per share, the Company's common
stock will be delisted from The NASDAQ Capital Market. Additional risks and uncertainties that could
cause actual results to differ materially from those indicated by these forward-looking statements are
discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2010, as amended, and other reports filed by the Company from time to time with
the SEC. The Company undertakes no obligation to update any of the information included in this release,
except as otherwise required by law.

PBI filed a registration statement (including a prospectus) with the SEC for the offering to which this
communication may relate. Before you invest, you should read the prospectus in that registration
statement for the offering and other documents PBI has filed with the SEC for more complete information
about PBI and the offering. You may get these documents for free by visiting EDGAR on the SEC Web
site at www.sec.gov.
request.

http://www.pressurebiosciences.com